The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2023 | Using mass spectrometry & NGF to analyze MRD negativity & long-term disease control in NDMM
Noemí Puig, MD, PhD, University Hospital Salamanca, Salamanca, Spain, shares some insights into a study which evaluated the use of mass spectrometry and next-generation flow (NGF) to analyze measurable residual disease (MRD) and long-term disease control in patients with multiple myeloma. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
